EPAS1 and liver cancer: Hou et al. (92) demonstrated that YTHDF2 downregulation in HCC is regulated by HIF-2α, and an HIF-2α antagonist (PT2385) can upregulate YTHDF2 in vitro (without changing its cytosolic distribution) and repress liver cancer.